mighties at the MDA Conference

myTomorrows Team 24 Mar 2023

5 mins read

share this post

This week, the myTomorrows team and I attended the MDA clinical and scientific conference in Dallas, Texas.

The Muscular Dystrophy Association (MDA) started in 1950 and works tirelessly to transform the lives of people living with muscular dystrophy, amyotrophic lateral sclerosis (ALS) and related neuromuscular diseases. Alongside their research and advocacy work, they host an annual conference designed to bring together the neuromuscular disease (NMD) community, inviting renowned researchers, industry leaders, clinicians, patients, caregivers, academicians, and advocates. It’s the largest of its kind and offers the unique opportunity for those within the muscular dystrophy field to build connections, networks and collectively push forward development of better care and treatment.

For myTomorrows, we were excited to contribute, connect with our network and demonstrate how our go-to platform for pre-approval access, linking patients with unmet medical needs, including those with Muscular Dystrophy, with treatments in development worldwide.

We kicked off our trip by paying a visit to our esteemed colleague, Dr. Diana Castro. Dr. Castro is a Pediatric Neurologist and has just opened her own clinic in Denton, outside of Dallas, where she will support patients with neuromuscular diseases. Dr. Castro makes use of the myTomorrows platform that supports patients with discovering and accessing clinical trials. By doing this, she supports her patients to navigate options and ensures that her clinical trials are visible to patients outside of her clinic. To find out more about her inspiring story, read our recent blog profiling Dr. Castro. Adrianne Rivard, myTomorrows Medical Science Liaison, and I were humbled and honored to have been invited to attend the clinic’s grand opening. It was a hugely special occasion, celebrating Dr. Castro’s distinctive, personal, and innovative approach to community-based patient care.

Next up, at the MDA conference, our booth was ready to welcome existing connections as well as new ones. Over the course of the next three days, we met with over a hundred healthcare professionals, physicians, patients, advocates, and leaders in the biopharma industry. It was truly inspiring to meet so many individuals, all motivated by the same patient-centric mission to improve quality of life and give patients more options and better access. At our stand, we had conversations with physicians which reinforced the need for patient-focused support when potential clinical trials are being investigated. We gave out helpful materials to treating physicians and clinical researchers designed to explain the myTomorrows’ mission, purpose and highlight our relevance within the industry. We showcased our easy-to-use platform through demos, showing how our personalized and streamlined approach empowers both physicians and patients to manage treatment with confidence. We’d like to thank everyone who visited us, your time, expertise and passion was really appreciated.

A key priority for us at the conference was to further our own understanding of current developments and innovations. We joined a series of lectures and workshops, demonstrating cutting edge research advancements and clinical achievements in neuromuscular disease. For me, to be a part of that wider discussion, side by side with so many distinguished guests and leaders, was awe inspiring. I was fascinated by the session led by Barry Byrne MD PhD on Gene Therapy. Put simply, this exploration has the power to change the landscape of therapies for the future, and hugely impact the NMD community. There was a strong focus about Gene Therapy throughout the conference, drawing big crowds. On one occasion, there were so many attendees for a session, a separate room had to set-up for the overflow of interested parties! We learnt about new and emerging therapies, as well as practical considerations for the Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) fields – the learnings from which will no doubt inform our future strategy at myTomorrows. As an organization which prides itself on keeping up to date with the latest tech and treatments, we relentlessly focus on how we can best adapt to ensure patients worldwide have access to the most up to date information on the entire treatment landscape. My time at the conference truly reinforced my belief in the importance and relevance of the myTomorrows mission.

One of the elements which struck me most, was the sheer power, support and care the MDA gives the neuromuscular disease community. By facilitating and creating a space which brought together people from every side of the coin – from patient, to caregiver, to physician to pharma provider, the MDA created conditions which enabled a wider, deeper, and more diverse discussion about what is really needed to further neuromuscular development. It offered numerous opportunities to network and meet new people within a relaxed atmosphere. Their relentless passion and care matches that of myTomorrows and coming back from the conference I’m even more fired up to help more patients than ever before discover pathways to treatment.

We’re keen to continue the wonderful conversations and connections we made at the MDA conference. To help make this happen, my Medical Community team and I are excited to announce we will soon launch a new webinar series, designed at supporting clinical researchers, treating physicians and principal investigators – so watch this space to get involved!

share this post

Duchenne Muscular DystrophyMDA ConferenceMuscular Dystrophy Association

myTomorrows Team 24 Mar 2023

more articles

view all blogs
DMD clinical trial eligibility
Duchenne Muscular Dystrophy
Clinical Trials

How to Find Duchenne Muscular Dystrophy Clinical Trials Your Child May Be Eligible For

Madeleine Pagel

13 Nov 2026

18 mins read

DMD clinical trial eligibility
Duchenne Muscular Dystrophy
Clinical Trials

What Should Patients and Caregivers Know About DMD Clinical Trial Eligibility?

Chris Anselmo

6 Nov 2026

16 mins read

Female doctor looking at tablet an d laptop in office setting
How to find clinical trials
AI pre-screening
Clinical Trials

From Search to Shortlist: How to Find Relevant Recruiting Clinical Trials for Your Patients

Adrianne Rivard

3 Nov 2026

11 mins read

Patient-Centric Recruitment
Patient Recruitment
Clinical Trials

Patient-Owned Health Data Is Reshaping Clinical Research, From Recruitment to Longitudinal Evidence

Dennis Akkaya

6 Oct 2026

11 mins read

Patient Recruitment
Patient-Centric Recruitment
Clinical Trials

The Shift from Study-Centric to Patient-Centric Clinical Trial Recruitment

Adrianne Rivard

25 Sep 2026

10 mins read

Smiling photo of mother and son
Eligibility criteria
Clinical Trials

Ready, willing and prepared: living with LGMD2i and navigating clinical trials

Laura Haggqvist

28 Aug 2026

15 mins read

Patient Recruitment
ALS Clinical Trials
ALS

Why Only 1 in 4 People with ALS Can Realistically Access Clinical trials

Dennis Akkaya

21 Aug 2026

12 mins read

Two people sitting outside having a discussion, one in a wheelchair
ALS Clinical Trials

How to Find ALS Clinical Trials That Are Right for You

Madeleine Pagel

14 Aug 2026

14 mins read

Couple assessing clinical trial inclusion and exclusion criteria
Clinical Trials
Eligibility criteria

Clinical Trial Inclusion and Exclusion Criteria: How to Know if You May Qualify

Andrea Enguita

3 Aug 2026

18 mins read

Clinical Trials
AI
Research

The Referral Readiness Gap: What 100 U.S. Clinical Trial Sites Told Us About Referral Quality

Adrianne Rivard

14 Jul 2026

8 mins read